2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.45 Study of the Mutational Profile of EGFR-Mutated Lung Cancer in the Russian Population on the Example of the City of Moscow

EP.12A.45 Study of the Mutational Profile of EGFR-Mutated Lung Cancer in the Russian Population on the Example of the City of Moscow

Back to course

Pdf Summary

The study conducted by Ilia Kanner at Lomonosov Moscow State University and Moscow City Oncological Hospital 62 examines the mutational profile and survival outcomes of EGFR-mutated lung cancer patients in Moscow. The research involved 5,561 lung cancer patients, with 1,113 found to harbor EGFR mutations. Among these, 74% were female, and the median age of the sample was 66, ranging from 29 to 94 years.<br /><br />The study focused on identifying the specific exon mutations within the EGFR gene, finding such mutations in 959 patients. The survival analysis concentrated on 114 patients with locally advanced or metastatic EGFR-positive non-small cell lung cancer (NSCLC), who had not received prior anti-cancer therapy and were free of concurrent malignant tumors. These patients received first-line targeted therapy.<br /><br />The median progression-free survival (PFS) in this cohort was 13.3 months, with a confidence interval (CI) ranging from 10.9 to 15.5 months. The overall survival (OS) median was calculated at 28.8 months, with a 95% CI between 25.2 and 33.8 months.<br /><br />In conclusion, the distribution of EGFR mutations in the studied population aligns with global data. The survival outcomes, including PFS and OS, are consistent with findings from the FLAURA phase III clinical trial, one of the benchmarks in EGFR-positive lung cancer studies. This research adds valuable data specific to the Russian population, contributing to the broader understanding of EGFR-mutated lung cancer worldwide.

Asset Subtitle

Ilia Kanner

Meta Tag

Speaker Ilia Kanner

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

EGFR-mutated lung cancer

Lomonosov Moscow State University

Moscow City Oncological Hospital 62

mutational profile

survival outcomes

non-small cell lung cancer

progression-free survival

overall survival

FLAURA trial

Russian population